Russian Rusnano aims to restore control over UK pharma asset - Ascension Healthcare

The Russian nano and pharmaceutical company Rusnano will seek to overturn the High Court of England and Wales's permission to forcefully sell the assets of the England-based subsidiary - Ascension Healthcare, as it hopes to continue the development of its pharmaceutical business in the UK, reports The Pharma Letter’s local correspondent.

An official spokesman of Rusnano recently said in an interview with the Russian Vedomosti business paper, the external management introduced in Ascension Healthcare in fall 2024 allowed the management of this company to buy out its assets at a significantly reduced price.

Financing hit by Russia’s conflict with Ukraine

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK